COMPASS

COMPASS is a randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in patients with coronary artery disease (CAD) or peripheral arterial disease (PAD).

Learn More

COMPLETE

The primary objective is to determine whether, on a background of optimal medical therapy with low dose ASA and ticagrelor, a strategy of multi-vessel revascularization involving staged...

Learn More

HOPE

The objective of HOPE was to evaluate the use of the ACE inhibitor, ramipril, and of vitamin E in high-risk patients with chronic stable vascular disease and/or diabetes and additional risk factor(s).

Learn More

HOPE-3

To evaluate whether a cholesterol lowering drug, rosuvastatin, and a combination blood pressure lowering pill, candesartan/ hydrochlorothiazide, used alone or together can reduce the risk of heart attack...

Learn More

INTERHEART

The INTERHEART study found that nine easily measurable and modifiable risk factors could explain more than 90 per cent of the risk of a heart attack globally and in all regions and major ethnic groups of the world.

Learn More

INTERSTROKE

Stroke is the most common cause of adult disability and the third leading cause of death worldwide, most of which occurs in low-income countries.

Learn More

MANAGE

To assess the impact of dabigatran (a direct thrombin inhibitor) in patients suffering myocardial injury after noncardiac surgery (MINS).

Learn More

OASIS 4 CURE

To evaluate the efficacy and safety of clopidogrel when given with aspirin patients with non- ST-segment elevation acute coronary syndromes.

Learn More

ORIGIN

To evaluate the effects of lantus (insulin glargine) versus standard care, and of Omega-3 fatty acids versus placebo, in reducing cardiovascular morbidity...

Learn More

PURE

The PURE study examines the impact of urbanization, modernization and globalization on the development of risk factors , and CVD.

Learn More

RE-LY

To demonstrate the efficacy and safety of dabigatran etexilate in patients with non-valvular atrial fibrillation, for the prevention of stroke and systemic embolism.

Learn More

RIVAL

To demonstrate the efficacy and safety of dabigatran etexilate in patients with non-valvular atrial fibrillation for the prevention of stroke and systemic embolism.

Learn More

VISION

To collect international data regarding major adverse vascular events. during non-cardiac surgery.

Learn More

Back To Top